In 58 men with oligometastatic hormone-sensitive prostate cancer, 177Lu-PSMA-617 vs deferred ADT cut 30-week progression (7% vs 93%) and lengthened median PFS (25 vs 5 months; HR 0.07) in this phase 2 trial; dry mouth was common (66%).
RCTn = 58
Privé et al. [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study